KNSA
NASDAQKiniksa Pharmaceuticals International plc
Price$78.58-1.19 (-1.49%)
01:30 PM07:45 PM
News · 26 weeks44-87%
2026-04-192026-10-11
Mix1890d
- Insider9(50%)
- SEC Filings4(22%)
- Earnings2(11%)
- Other2(11%)
- Analyst1(6%)
Latest news
25 items- ANALYSTWells Fargo initiated coverage on Kiniksa Pharmaceuticals with a new price targetWells Fargo initiated coverage of Kiniksa Pharmaceuticals with a rating of Overweight and set a new price target of $87.00
- PRKiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare ConferenceLONDON, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) today announced that management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026 at 8:45 a.m. Eastern Time. A live webcast of Kiniksa’s presentation will be accessible through the Investors section of the company’s website at www.kiniksa.com. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event. About KiniksaKiniksa is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating diseases by discovering, acquiring, develop
- INSIDERCHIEF FINANCIAL OFFICER Ragosa Mark covered exercise/tax liability with 4,404 units of Class A Ordinary Share and converted options into 9,104 units of Class A Ordinary Share, increasing direct ownership by 29% to 20,854 units (SEC Form 4)4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- INSIDERCHAIRMAN & CEO Patel Sanj K converted options into 31,318 units of Class A Ordinary Share and covered exercise/tax liability with 15,144 units of Class A Ordinary Share (SEC Form 4)4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- INSIDERCHIEF MEDICAL OFFICER Paolini John F. converted options into 8,328 units of Class A Ordinary Share and covered exercise/tax liability with 4,029 units of Class A Ordinary Share, increasing direct ownership by 7% to 69,922 units (SEC Form 4)4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- INSIDERCHAIRMAN & CEO Patel Sanj K converted options into 31,318 units of Class A Ordinary Share and covered exercise/tax liability with 15,144 units of Class A Ordinary Share (SEC Form 4)4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- INSIDERCHIEF OPERATING OFFICER Moat Ross converted options into 8,285 units of Class A Ordinary Share and covered exercise/tax liability with 4,007 units of Class A Ordinary Share, increasing direct ownership by 36% to 16,307 units (SEC Form 4)4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- INSIDERCHIEF ACCOUNTING OFFICER Megna Michael R converted options into 11,496 units of Class A Ordinary Share, covered exercise/tax liability with 5,531 units of Class A Ordinary Share, sold $369,380 worth of Class A Ordinary Share (4,600 units at $80.30) as part of a pre-agreed trading plan and was granted 279 units of Class A Ordinary Share, increasing direct ownership by 6% to 29,062 units (SEC Form 4)4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- SECSEC Form 144 filed by Kiniksa Pharmaceuticals International plc144 - Kiniksa Pharmaceuticals International, plc (0001730430) (Subject)
- INSIDERDirector Quart Barry D gifted 2,600 units of Class A Ordinary Share, decreasing direct ownership by 17% to 12,745 units (SEC Form 4)4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- PRKiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth ConferenceLONDON, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) today announced that management will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026 at 9:00 a.m. Eastern Time. A live webcast of Kiniksa’s presentation will be accessible through the Investors section of the company’s website at www.kiniksa.com. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event. About KiniksaKiniksa is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating diseases by discovering, acquiring, developi
- INSIDERDirector Levy Richard S converted options into 403 units of Class A Ordinary Share, increasing direct ownership by 2% to 22,359 units (SEC Form 4)4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- INSIDERDirector Cole G Bradley sold $299,092 worth of Class A Ordinary Share (3,673 units at $81.43) and gifted 4,500 units of Class A Ordinary Share, decreasing direct ownership by 53% to 7,172 units (SEC Form 4)4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- SECSEC Form 144 filed by Kiniksa Pharmaceuticals International plc144 - Kiniksa Pharmaceuticals International, plc (0001730430) (Subject)
- SECSEC Form 10-Q filed by Kiniksa Pharmaceuticals International plc10-Q - Kiniksa Pharmaceuticals International, plc (0001730430) (Filer)
- SECKiniksa Pharmaceuticals International plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Kiniksa Pharmaceuticals International, plc (0001730430) (Filer)
- PRKiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution– ARCALYST¨ (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth –– ARCALYST 2026 expected net product revenue increased to $980 - $995 million –– KPL-387 Phase 2 data demonstrated rapid and sustained reductions in pain and inflammation at 300 mg SC once-monthly, the dose level selected for Phase 3 –– KPL-387 pivotal Phase 3 trial in recurrent pericarditis now enrolling and dosing patients –– Conference call and webcast scheduled for 8:30 am ET today – LONDON, July 28, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for dise
- PRKiniksa Pharmaceuticals to Report Second Quarter 2026 Financial Results on July 28, 2026LONDON, July 23, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) announced today that it will host a conference call and live webcast on Tuesday, July 28, 2026 at 8:30 a.m. Eastern Time to report its second quarter 2026 financial results and recent portfolio execution. A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. Individuals interested in participating in the call via telephone may register here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and regist
- INSIDERSEC Form 4 filed by CHIEF STRATEGY OFFICER Malkani Dhiraj H4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- INSIDERSEC Form 3 filed by new insider Malkani Dhiraj H3 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- INSIDERDirector Quart Barry D converted options into 2,799 units of Class A Ordinary Share, increasing direct ownership by 22% to 15,345 units (SEC Form 4)4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- INSIDERDirector Popovits Kimberly J converted options into 2,799 units of Class A Ordinary Share, increasing direct ownership by 22% to 15,345 units (SEC Form 4)4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- INSIDERCHAIRMAN & CEO Patel Sanj K converted options into 900,000 units of Class A Ordinary Share (SEC Form 4)4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- INSIDERDirector Mccain Tracey L converted options into 2,799 units of Class A Ordinary Share, increasing direct ownership by 22% to 15,345 units (SEC Form 4)4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- INSIDERDirector Malley Thomas converted options into 2,799 units of Class A Ordinary Shares, increasing direct ownership by 22% to 15,345 units (SEC Form 4)4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
KNSA FAQ
7 questionsWhat does Kiniksa Pharmaceuticals International plc do?
Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its product candidates include Rilonacept, which is in Phase III clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody that is in Phase II clinical trials for the treatment of giant cell arteritis; and Vixarelimab, a monoclonal antibody, which is in Phase...Where does KNSA stock trade?
Kiniksa Pharmaceuticals International plc (KNSA) is listed on NASDAQ.What sector and industry is KNSA in?
Kiniksa Pharmaceuticals International plc operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Kiniksa Pharmaceuticals International plc go public?
Kiniksa Pharmaceuticals International plc (KNSA) completed its IPO in 2018.What are analysts saying about KNSA?
Kiniksa Pharmaceuticals International plc has had 7 recent analyst actions on file. The most recent action was from Wells Fargo: Overweight on 2026-09-30. Recent price targets range from $3400.00 to $4000.00.What companies are similar to KNSA?
Notable peers in the same industry include MEIP (MEI Pharma Inc.), SYRS (Syros Pharmaceuticals Inc.), ALNA (Allena Pharmaceuticals Inc.), ARDS (Aridis Pharmaceuticals Inc.), RVPH (Reviva Pharmaceuticals Holdings Inc.). Compare KNSA side-by-side with any of them on Quantisnow.How can I track KNSA on Quantisnow?
Quantisnow aggregates Kiniksa Pharmaceuticals International plc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow KNSA to receive live email and push alerts on every new disclosure.